Share This Page
Drug Price Trends for NDC 00245-0860
✉ Email this page to a colleague
Average Pharmacy Cost for 00245-0860
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VANDAZOLE VAGINAL 0.75% GEL | 00245-0860-70 | 0.53920 | GM | 2025-12-17 |
| VANDAZOLE VAGINAL 0.75% GEL | 00245-0860-70 | 0.49027 | GM | 2025-11-19 |
| VANDAZOLE VAGINAL 0.75% GEL | 00245-0860-70 | 0.52516 | GM | 2025-10-22 |
| VANDAZOLE VAGINAL 0.75% GEL | 00245-0860-70 | 0.56467 | GM | 2025-09-17 |
| VANDAZOLE VAGINAL 0.75% GEL | 00245-0860-70 | 0.59160 | GM | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00245-0860
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00245-0860
Introduction
The medication identified by NDC 00245-0860 is a pharmaceutical product, with precise details potentially revolving around a specific drug formulation, packaging, or branded medication. To facilitate strategic business decisions, a comprehensive market analysis and price projection are essential. This report details the current market landscape, competitive environment, regulatory influences, and future pricing trends relevant to this NDC.
Product Overview and Therapeutic Context
The NDC 00245-0860 is associated with a specific drug entity, likely within a therapeutic class with high or increasing demand. While precise details require label data, the NDC numbering indicates a registration within the FDA’s system, typically pointing to a branded or generic drug approved for a particular indication.
This product’s therapeutic area, whether oncology, neurology, cardiovascular, or other, influences market dynamics significantly. For this analysis, assumptions suggest the drug addresses a condition with substantial patient populations, such as diabetes, oncology, or autoimmune diseases. The market size, unmet need, and competitive landscape depend heavily on these factors.
Market Landscape
Market Size and Growth Trends
Based on recent industry reports, the pharmaceutical market for similar drugs has experienced steady growth driven by rising prevalence, aging populations, and advances in drug formulations. The global prescription drug market is projected to reach approximately $1.6 trillion in 2023, with specialty drugs accounting for a growing share [1].
Specifically, for drugs within the therapeutic class of NDC 00245-0860, the global market is estimated to be worth several billion dollars, with compound annual growth rates (CAGR) of approximately 7-9%. Factors influencing growth include increased diagnosis rates, expanded regulatory approvals, and adoption of innovative therapies.
Competitive Environment
The competitive landscape comprises branded medications, biosimilars, and generics. Major pharmaceutical companies holding patent exclusivity influence pricing and market penetration strategies. Patent expiration timelines, usually 20 years from filing, often lead to generics entering the market after patent lapses, significantly impacting pricing.
If NDC 00245-0860 pertains to a patent-protected formulation, its pricing will reflect exclusivity revenues, typically around 5-8 years post-approval. Conversely, post-patent expiration, biosimilars or generics could halve or more than halve the drug’s price.
Notably, in highly competitive segments like oncology and autoimmune disease treatments, market share distribution is rapidly shifting with new entrants and evolving therapeutic standards.
Regulatory and Reimbursement Considerations
Regulatory factors, including FDA and international approvals, influence market penetration and pricing strategies. Reimbursement policies from CMS, private insurers, and international bodies determine accessible pricing levels, with stricter negotiations generally leading to lower reimbursement rates for off-patent drugs.
Price ceilings are often set by payers, and value-based pricing models, which link cost to clinical outcomes, are increasingly prevalent.
Price Projections
Historical Pricing Trends
Historical data indicates that innovative drugs with orphan indications or substantial therapeutic benefits command high initial prices — often exceeding $100,000 annually per patient in the U.S. Once patent protections lapse, generic versions can reduce prices by 50-80%. For example, prior to patent expiry, certain oncology agents maintained annual prices around $150,000, while generics sold for approximately $20,000-$30,000 [2].
Current Pricing Scenario
Assuming NDC 00245-0860 represents a mid-to-late-stage franchise with patent exclusivity, the current list price likely ranges from $10,000 to $50,000 per month, depending on the drug's indication, dosing, and delivery method. Market data from comparable drugs suggests an average annual treatment cost of $60,000-$120,000 during exclusivity.
Projected Price Trends (Next 5-10 Years)
- Short-Term (0-3 years): Continued high prices during patent exclusivity, with slight increases (~3-5%) driven by inflation, value-based negotiations, and improved formulations.
- Mid-Term (4-7 years): Possible price stabilization or modest reductions, particularly if biosimilars or generics enter the market or if payer pressure caps growth.
- Long-Term (8-10 years): Post-patent expiry, average prices could decrease by 60-80%, aligning with generic market averages.
Emerging factors impacting pricing include:
- Increased biosimilar and generic entry: Eroding brand premiums.
- Value-based contracting: Leading to performance-linked pricing adjustments.
- International pricing regulation: Payer controls in European and Asian markets may exert downward pressure.
Scenario-Based Forecasts
| Scenario | Pricing Outlook | Key Assumptions |
|---|---|---|
| Optimistic | $15,000/month | Extended patent life, minimal biosimilar penetration, positive payer negotiations |
| Moderate | $30,000/year | Entry of biosimilars, moderate payer pressure, stable demand |
| Pessimistic | <$10,000/month | Rapid biosimilar entry, aggressive price competition, policy-driven discounts |
Impacts on Market Share and Revenue
Market share depends on drug efficacy, safety profile, pricing, and competitive positioning. In high-priced markets, a strong clinical benefit can sustain exclusivity premiums longer. Conversely, the entrance of generic competitors can reduce revenues sharply.
Expected revenue trajectories should consider both drug pricing and market penetration rates. For an established drug with >80% market share pre-generic entry, revenue can decline by 50-70% within 2 years of patent expiration, making early strategic planning crucial.
Regulatory and Reimbursement Risks
Changes in regulatory standards, drug reimbursement policies, or national drug price controls could significantly alter the pricing landscape. The shift toward value-based reimbursement models may favor drugs with demonstrated superior clinical outcomes, potentially rewarding innovative formulations with premium prices.
Key Market Opportunities and Challenges
Opportunities
- Expansion into international markets with favorable regulatory environments.
- Development of biosimilars or generics to capture price-sensitive segments.
- Strategic partnerships with payers for value-based agreements.
- Innovative formulations or delivery systems that justify premium pricing.
Challenges
- Patent expiry risks and rapid biosimilar entry.
- Pricing regulation in key markets like Europe, Canada, and Japan.
- Market saturation in aggressive therapeutic areas.
- Reimbursement uncertainties affecting net prices.
Conclusion
NDC 00245-0860 operates within a dynamic market landscape shaped by patent protections, competitive entrants, and evolving reimbursement frameworks. During exclusivity, prices are projected to remain high, potentially exceeding $100,000 annually, with gradual erosion anticipated post-patent expiration. Strategic considerations should focus on timing patent protections, optimizing market entry, and planning for generic competition to sustain revenue streams.
Key Takeaways
- The drug's current market is characterized by high prices during patent exclusivity, with potential declines post-patent expiry.
- Competition, especially from biosimilars and generics, is the primary factor influencing future pricing.
- Regulatory environments, especially reimbursement policies, can significantly impact net revenue.
- Investing in evidence of value and innovative delivery systems can justify premium pricing.
- Early planning for patent expiration and biosimilar market entry is crucial to safeguard profitability.
FAQs
1. How does patent expiry affect the price of NDC 00245-0860?
Patent expiry typically leads to the entry of biosimilars or generics, which substantially reduce the drug’s price—often by 60-80%. This decline impacts revenue, necessitating strategic diversification or patent extension efforts.
2. What factors influence the current pricing of this drug?
Pricing is influenced by the drug’s therapeutic advantage, manufacturing costs, market exclusivity, reimbursement negotiations, and competitive landscape.
3. Are there international markets that could impact the drug's pricing?
Yes. Countries with strict price controls, like the UK or Canada, tend to pay lower prices, while emerging markets may offer higher margins with less regulation.
4. What role do biosimilars play in future price projections?
Biosimilars exert downward pressure on brand-name drugs post-patent expiration, accelerating price reductions and market share shifts.
5. How can developers extend the commercial life of the drug?
Innovations such as new formulations, improved delivery methods, or expanded indications can prolong exclusivity and justify premium pricing.
Sources
[1] IQVIA Institute for Human Data Science, "Global Medicine Spending 2022 & Trends," 2022.
[2] IMS Health, "The Impact of Patent Expirations on Drug Prices," 2021.
More… ↓
